LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials

 (BUSINESS WIRE)--Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide.

The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele fractions ≥0.01%, are associated with increased relapse and worse overall survival.3 Recent studies show emerging evidence that pre-transplant MRD testing for NPM1 and FLT3-ITD identifies AML patients in remission who are most likely to relapse or experience poor survival.3,4,5

With this approval, LabPMM is helping to transform the landscape of AML research, treatment and drug development. By using MRD as a surrogate endpoint in clinical trials, instead of relying solely on overall survival (OS), pharmaceutical companies can accelerate their drug development timelines. This is particularly valuable in acute disease, where time is of the essence, and earlier intervention can dramatically improve patient outcomes.

“We are proud to receive New York State approval for our NPM1 MRD Assay by NGS, marking our second assay approved by New York State this year,” said Jordan Thornes, V.P., Global Clinical Laboratory Operations at LabPMM. “This milestone reflects our continued dedication to advancing precision diagnostics in cancer care. With this latest approval, we’re further empowering clinicians with sensitive, reliable tools to detect residual disease and guide treatment decisions with confidence.”

LabPMM’s NPM1 and FLT3 ITD MRD Assays are standardized next generation sequencing (NGS) tests that complement the LeukoStrat® CDx FLT3 Mutation Assay, which is used to guide treatment selection for patients with AML. These services are offered in the U.S., European Union, and across Asia to ensure patients around the world have access to high-quality, standardized testing and to support the development of cutting-edge cancer treatments. LabPMM remains committed to advancing precision medicine and improving outcomes for patients worldwide. For more information about the NPM1 MRD Assay and LabPMM’s full test menu, please visit https://invivoscribe.com/clinical-lab-services/ or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.

About Invivoscribe

Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.

Falini, B. et al. Blood. 2020; 136(15):1707–1721.

Kelemen, K. Life. 2022; 12(1): 109.

Dillon, L. et al. JAMA. 2023; 329(9):745-755

Dillon, L. et al. JAMA Oncology. 2024; 10(8)1104-1110

Levis, M. et al. Blood. 2025; 145(19):2138-2148.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250617961412/en/

Permalink

https://www.aetoswire.com/en/news/1806202547456

Contacts

inquiry@invivoscribe.com

DDC Enterprise Announces Up to $528 Million Raise to Accelerate Bitcoin Treasury Strategy

 NEW YORK - Tuesday, 17. June 2025 AETOSWire 

Landmark Funding Dedicated Exclusively to Bitcoin Acquisition Positions DDC to Become a Global Leader in Bitcoin Holdings

(BUSINESS WIRE)--DDC Enterprise Limited (NYSE: DDC) (“DDC” or the “Company”) today announced it has entered into three securities purchase agreements for a total of up to $528 million of gross proceeds to the Company, before placement agent fees and offering expenses. Investors include Anson Funds, Animoca Brands, Kenetic Capital, QCP Capital, and a network of leading institutional funds and individual Bitcoin investors. Substantially all of the capital raise will be dedicated to expanding the Company’s Bitcoin treasury. This transformative financing, among the largest single-purpose Bitcoin raises by any NYSE-listed company, is expected to accelerate DDC's mission to establish one of the most valuable corporate Bitcoin holdings.

Strategic Funding Structure: Institutional Confidence at Scale

$26 Million Equity PIPE Investment

The Company has entered into subscription agreements with premier investors including Animoca Brands, Kenetic Capital, QCP Capital, Jack Liu, Matthew Liu (Co-Founder, Origin Protocol), and other leading institutional funds and individual Bitcoin investors. Subject to standard closing conditions, DDC expects to issue up to 2,435,169 Class A Ordinary shares at an average price of $10.30 per share. The shares will be restricted for 180-days.

 

$300 Million Convertible Secured Note and $2 Million Equity Private Placement

With Anson Funds as the investor, an institutional investment firm with offices in the United States and Canada, the convertible secured note accrues no interest and will mature in 24 months. Pursuant to the Facility, the Company will issue a note in the aggregate principal amount of $25 million as its first tranche, with additional capacity of up to $275 million available in subsequent drawdowns upon mutual agreement of the parties. Anson Funds is also purchasing 307,693 Class A Ordinary shares for $2 million in a concurrent private placement.

 

$200 Million Equity Line

The $200 million equity line of credit (“ELOC”), also secured with Anson Funds, is designed to offer DDC maximum flexibility in accessing capital for dedicated BTC stacking. With the ELOC, upon its future commencement following registration, the Company can optimize market timing and can consistently make BTC purchases over time at management discretion.

Substantially all of the gross proceeds from the financings will be deployed to acquire Bitcoin.

Statement from Norma Chu, Founder, Chairwoman & CEO of DDC Enterprise

"Today is a defining moment for DDC Enterprise and our shareholders. This capital commitment of up to $528 million, backed by respected institutions from both traditional finance and the digital asset frontier, represents a strong mandate to execute an ambitious corporate Bitcoin accumulation strategy globally. Our vision is unequivocal: we are building the world's most valuable Bitcoin treasury.”

Ms. Chu, continued, “This funding is expected to propel DDC into one of the top global corporate Bitcoin holders. This investment by Anson Funds and the group of PIPE investors is a resounding validation of Bitcoin's important role in future corporate balance sheets. At DDC, we will deploy this capital with institutional discipline and unwavering conviction, cementing our position as the premier bridge between global capital markets and the Bitcoin ecosystem. DDC Enterprise is strongly positioned as the definitive publicly-traded vehicle for concentrated Bitcoin exposure and value creation. My focus will be on growing our BTC treasury and delivering attractive BTC yield consistently for our shareholders."

Maxim Group LLC acted as the exclusive financial advisor in connection with the offering. The closings of the financings are subject to the satisfaction of customary closing conditions.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About DDC Enterprise

DDC Enterprise Limited (NYSE: DDC) is spearheading the corporate Bitcoin treasury revolution while maintaining its foundation as a leading global Asian food platform. The Company has strategically positioned Bitcoin as a core reserve asset, executing an aggressive accumulation strategy. While continuing to grow its portfolio of culinary brands – including DayDayCook, Nona Lim, and Yai's Thai – DDC is now at the vanguard of public companies integrating Bitcoin into their financial architecture.

Caution Regarding Forward-Looking Statements

Certain statements in this announcement are forward-looking statements.

Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. Examples of forward-looking statements include those related to business prospects, accumulation of Bitcoin, and the Company’s goals and future activity under the financing transactions described above, including the statements on the closings of the offerings and the satisfaction of closing conditions and use of proceeds in the offerings. These statements are subject to uncertainties and risks including, but not limited to, the risk factors discussed in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 20-F, 6-K and other reports, including a Form 6-K which with copies of the definitive documents related to the above transactions, to be filed with the Securities and Exchange Commission (“SEC”) and available at www.sec.gov. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250616739727/en/

Permalink

https://www.aetoswire.com/en/news/54276433

Contacts

 

For Bitcoin Investor Relations:

Yujia Zhai | ddc@orangegroupadvisors.com

Media: pr@daydaycook.com

NTT DATA Research Reveals C-Suite Misalignment Over GenAI Adoption

LONDON - Tuesday, 17. June 2025


    Nearly half of CISOs have negative sentiments about GenAI rollouts, despite CEO optimism
    CEOs are all-in on GenAI, but CISOs warn that security gaps and aging infrastructure are holding back progress
    Alignment requires stronger governance and dedicated investment

 

(BUSINESS WIRE)--NTT DATA, a global leader in digital business and technology services, today launched its new report, “The AI Security Balancing Act: From Risk to Innovation,” highlighting the opportunities and risks AI presents in cybersecurity. The findings show a misalignment among C-Suite leaders when it comes to business goals and operational readiness for GenAI deployment.

The report, which includes data from an NTT DATA survey of more than 2,300 senior GenAI decision makers, comprising 1,500 *C-Suite leaders across 34 countries, found that while CEOs and business leaders are committed to GenAI adoption, CISOs and operational leaders lack the necessary guidance, clarity and resources to fully address security risks and infrastructure challenges associated with deployment.

The C-Suite disconnect

Nearly all (99%) C-Suite executives are planning further GenAI investments over the next two years, with 67% of CEOs planning significant commitments.

In parallel, 95% of CIOs and CTOs report that GenAI has already driven, or will drive, greater cybersecurity investments, with organizations ranking improved security as one of the top three business benefits realized from GenAI deployment in the last 12 months.

Yet, even with this optimism, there is a notable disconnect between strategic ambitions and operational execution with nearly half of CISOs (45%) expressing negative sentiments toward GenAI adoption. More than half (54%) of CISOs say internal guidelines or policies on GenAI responsibility are unclear, yet only 20% of CEOs share the same concern – revealing a stark gap in executive alignment.

Despite feeling cautious about the deployment of GenAI, security teams still acknowledge its business value. In fact, 81% of senior IT security leaders with negative sentiments still agree GenAI will boost efficiency and impact the bottom-line.

Organizational operations not ready for GenAI

NTT DATA’s research further reveals a critical gap between leadership’s vision and the capabilities of their teams. While 97% of CISOs identify as decision makers on GenAI, 69% acknowledge that their teams lack the necessary skills to work with the technology.

In addition, only 38% of CISOs say their GenAI and cybersecurity strategies are aligned compared to 51% of CEOs.

Adding to the complexity, 72% of organizations surveyed still lack a formal GenAI usage policy and just 24% of CISOs strongly agree that their organization has a robust framework for balancing risk with value creation.

Legacy tech limiting GenAI adoption

Beyond internal misalignment, 88% of security leaders said legacy infrastructure is greatly affecting business agility and GenAI readiness, with modernizing IoT, 5G and edge computing identified as essential for future progress.

To navigate these obstacles, 64% of CISOs are prioritizing co-innovation with strategic IT partners rather than relying on standalone AI solutions. Notably, security leaders #1 top criteria when assessing GenAI technology partners is end-to-end GenAI service offerings.

"As organizations accelerate GenAI adoption, cybersecurity must be embedded from the outset to reinforce resilience. While CEOs champion innovation, ensuring seamless collaboration between cybersecurity and business strategy is critical to mitigating emerging risks," said Sheetal Mehta, Senior Vice President and Global Head of Cybersecurity at NTT DATA, Inc. "A secure and scalable approach to GenAI requires proactive alignment, modern infrastructure and trusted co-innovation to protect enterprises from emerging threats while unlocking AI’s full potential."

"Collaboration is highly valued by line-of-business leaders in their relationships with CISOs. However, disconnects remain, with gaps between the organization's desired risk posture and its current cybersecurity capabilities,” said Craig Robinson, Research Vice President, Security Services at IDC. “While the use of GenAI clearly provides benefits to the enterprise, CISOs and Global Risk and Compliance leaders struggle to communicate the need for proper governance and guardrails, making alignment with business leaders essential for implementation."

Download the full report here, and visit our website to learn more about NTT DATA’s AI services for cybersecurity.

Methodology

The report is based on insights from 2,300 senior GenAI decision-makers across 34 countries. 68% of respondents were from the C-suite, including CEOs, CISOs, CIOs, CTOs, CDOs, COOs, CCOs, CFOs, CHROs, and CSEs. 27% held Vice President, Head of, or Director-level roles, while 5% were senior managers or specialists. This research was independently conducted for NTT DATA by Jigsaw Research, a global strategic insight agency.

About NTT DATA

NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at nttdata.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250617433963/en/

Permalink
https://www.aetoswire.com/en/news/1706202547444

Contacts

Media Contact
Lori Bosio
lori.bosio@nttdata.com

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

 ZUG, Switzerland 

An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1

Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis1-3

This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4

 

(BUSINESS WIRE)--Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years.1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617336479/en/

 

“These promising data go even further in highlighting the extensive benefits of Nemluvio. As this treatment becomes available in more countries around the world, it’s highly encouraging to see its robust evidence base continue to expand and strengthen.”

 

BALDO SCASSELLATI SFORZOLINI, M.D., PHD.

GLOBAL HEAD OF RESEARCH & DEVELOPMENT

GALDERMA

 

 

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules, which have a substantial impact on patients’ quality of life.5-7 Nemluvio is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31.8,9,10 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation, skin barrier dysfunction, and fibrosis in prurigo nodularis.8-11 It is also the first and only biologic approved for prurigo nodularis as well as atopic dermatitis with four-week dosing intervals from the start of treatment.9,10

The OLYMPIA long-term extension study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and includes 508 patients from the phase II trial or the phase III OLYMPIA 1 and 2 trials.1 Results show that treatment with Nemluvio is associated with sustained and clinically meaningful improvements in symptoms of prurigo nodularis during prolonged treatment up to two years.1 At Week 100 in evaluable patients, the interim analysis shows that:

More than 90% and 70% achieved at least a four-point improvement in itch, and being itch free or nearly itch free respectively, as measured by the Peak-Pruritus Numerical Rating Scale1

At least 80% achieved 76‑100% healed pruriginous lesions1

Approximately 75% reached clearance or almost-clearance of skin nodules when assessed using the Investigator’s Global Assessment score1

Nemluvio was well tolerated in the long-term treatment of prurigo nodularis and no new safety signals were identified in this study to date.1

 

“These impressive results give us even more confidence in the value of nemolizumab – a much-needed innovative medicine that has the potential to deeply impact the prurigo nodularis treatment landscape. With this new treatment now approved in multiple markets including the EU and U.S., I’m thrilled to be able to see its meaningful impact in the real world.”

 

PROF. SONJA STÄNDER

LEAD INVESTIGATOR OF THE OLYMPIA STUDIES IN EUROPE

UNIVERSITY HOSPITAL MUNSTER, GERMANY

 

 

This follows presentation of results from the ARCADIA long-term extension study at the RAD Conference earlier this month, which showed that treatment with Nemluvio was well tolerated and associated with sustained and increased improvements in symptoms of atopic dermatitis during prolonged treatment up to two years.4

Nemluvio was first approved in August 2024 by the United States Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis.9 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.9 To date, Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including the European Commission. Additional reviews and submissions are ongoing.

Galderma will also host a symposium at ICD, exploring the latest advances in addressing itch in both prurigo nodularis and atopic dermatitis. Separately, the company will share new data from across its Therapeutic Dermatology portfolio in acne, non-melanoma skin cancer, and rosacea.

More details on Galderma’s scientific presentations at ICD can be found here.

About Nemluvio

Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.12,13

About prurigo nodularis

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.5-7 It is an underrecognized and underdiagnosed skin condition, and there are limited studies investigating its prevalence.11,14,15

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

Ständer S, et a. Nemolizumab long-term efficacy and safety up to 100 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis. Presented at International Congress of Dermatology; June 18-21, 2025; Rome, Italy.

ClinicalTrials.Gov. A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501679). Available online. Accessed May 2025

ClinicalTrials.Gov. Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666). Available online. Accessed May 2025

Silverberg, JI, et al. Nemolizumab long-term safety and efficacy up to 104 weeks in the ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis. Presented at Revolutionizing Atopic Dermatitis Conference 2025; June 6-7; Nashville, United States.

Huang AH, et al. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183

Pereira MP, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi: 10.1111/jdv.14570

Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi: 10.1097/itx.0000000000000042

Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013

Nemluvio U.S. Prescribing Information. Available online. Accessed May 2025

Nemluvio European Medicines Agency. Summary of Product Characteristics. Available online. Accessed May 2025

Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039–2048. doi: 10.1007/s13555-022-00782-2

Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed May 2025

Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed May 2025

Ständer S, et al. Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis. JAAD Int. 2020;2:28-30. doi: 10.1016/j.jdin.2020.10.009

Huang AH, et al. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140(2):480-483.e4. doi: 10.1016/j.jid.2019.07.697

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250617336479/en/

Permalink

https://www.aetoswire.com/en/news/1806202547455

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

SINOVAC Announces New Board Member

 BEIJING - Wednesday, 18. June 2025 AETOSWire  

(BUSINESS WIRE) -- Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the “Board”) and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang’s resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board.

Mr. Hsu is a General Partner and Portfolio Manager at OrbiMed, one of the world’s largest dedicated healthcare investment firms, managing over $17 billion in assets. Mr. Hsu brings extensive investment experience in the biotechnology industry and China. He joined OrbiMed in 2002 and has been a Portfolio Manager since 2005, leading the public equity team’s biotech and emerging markets efforts. He has been responsible for overseeing the firm’s public equity investments in China since 2009 and the firm’s investment in SINOVAC since 2013. Prior to joining OrbiMed, Mr. Hsu worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. He received an A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School.

Following this appointment, the Board consists of four members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven H. Borho, CFA, and Mr. Hsu. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Mr. Hsu. The Compensation Committee and the Corporate Governance and Nominating Committee of the Board each consists of Dr. Li, Mr. Lo and Mr. Hsu.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under “Category 1 Preventative Biological Products” and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please visit the Company’s website at www.sinovac.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250617453752/en/

Permalink

https://www.aetoswire.com/en/news/1806202547465

Contacts

Sinovac Biotech Ltd.

Helen Yang

Tel: +86-10-8279 9779

Email: ir@sinovac.com

Bureau Veritas Accelerates its LEAP | 28 Strategy Execution and Evolves its Executive Committee

 PARIS

(BUSINESS WIRE) -- Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC) is accelerating the execution of its LEAP | 28 strategy to reach its vision of being the preferred partner for its customers’ excellence and sustainability. Taking LEAP | 28 to the next level, Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment, strengthening its geographical platform with scalable Product Line structures, and optimizing its operations to enhance agility and effectiveness.

Since the strategy launch in March 2024, LEAP | 28 strategy execution has progressed steadily in all three pillars – Portfolio, Performance & People - and is now reaching an important stage requiring an evolution of the operating model. The new structure will empower the regions with scalable Product Lines, enabling global offers development, unlocking greater cross-selling opportunities, and driving growth and profitability.

The current six operating geographical Regions will be reorganized into four greater Regions: Americas, Europe, Asia Pacific, Middle East Caspian & Africa. The Product lines will be managed under three executive committee members who will lead: Industrials and Commodities, Urbanization and Assurance, and Consumer Products Services. These groupings at the executive committee level are aligned with customer workflows and market needs.

Considering the company ambition to scale performance programs across all the Regions and Product lines, a Chief Performance Officer and Executive Committee member role will be dedicated to lead the LEAP I 28 performance pillar and the overall optimization of key performance functions of operational excellence & performance, and sales & marketing. This role will drive the design, governance, and overall implementation and monitoring of these programs in coordination with other stakeholders across the organization.

All other Business and Support Functions will remain under their current leaders.

Hinda Gharbi, Chief Executive Officer of Bureau Veritas comments: “By directly connecting Product Lines to a simplified regional structure, we are strengthening our regional expertise and building deeper relations with our customers. This organization will also allow us to create more agility as we accelerate the execution of our LEAP | 28 strategy.

This new organization will leverage scale, benefit from a well-defined structure, thus speeding up decision making, performance impact, and innovation. I fully trust our Bureau Veritas Executive team to mobilize the entire organization to achieve our vision and deliver on our ambition.”

***

The transition period will extend from July 1st to the end of August 2025.

Effective September 1st 2025, the Group Executive Committee will be structured and composed as follows:

Regions:

Europe: Executive Vice-President > Vincent Bourdil

Middle East Caspian & Africa: Executive Vice-President > Khurram Majeed

Asia Pacific: Executive Vice-President > Surachet Tanwongsval

Americas: Executive Vice-President to be appointed before year end

Product Lines:

Industrials and Commodities: Executive Vice-President > Matthieu Gondallier De Tugny

Urbanization and Assurance: Executive Vice-President > Marc Roussel

Consumer Products Services: Executive Vice-President > Catherine Chen

Business Functions:

Corporate development & sustainability: Executive Vice-President > Juliano Cardoso

Chief Performance Officer: Executive Vice-President > Laurent Louail

Chief Digital & Innovation Officer: Executive Vice-President DxT (Digital & Technology) > Philipp Karmires

Support Functions:

Chief Financial Officer: Executive Vice-President > François Chabas

Chief People Officer: Executive Vice-President > Maria Lorente Fraguas

Legal affairs & Internal Audit: Executive Vice-President > Beatrice Place-Faget

***

About Bureau Veritas

Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change.

Created in 1828, Bureau Veritas’ 84,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.

Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.

For more information, visit http://www.bureauveritas.com, and follow us on LinkedIn.

***

Biographies:

Vincent Bourdil, appointed Executive Vice-President, Europe, joined Bureau Veritas in 2016 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Global Business Lines & Performance before becoming Executive Vice-President, Commodities, Industry & Facilities, Southwest Europe.

Khurram Majeed remains Executive Vice-President, Middle East, Caspian & Africa. He is a seasoned industry leader with over 23 years of senior management experience across energy, oil & gas, and other sectors. Khurram joined Bureau Veritas in 2024 as Executive Vice-President, Middle East, Caspian & Africa.

Surachet Tanwongswal remains Executive Vice-President Asia Pacific. He joined Bureau Veritas in 2024 as Executive Vice-President for Commodities, Industry & Facilities in Asia Pacific. Prior to this, Surachet held leadership roles at Ecolab and other global B2B companies.

Matthieu Gondallier de Tugny, appointed Executive Vice-President Industrials and Commodities, joined Bureau Veritas in 1994 and has held various technical, operational, and leadership roles in Marine & Offshore. His most recent role was Executive Vice-President, Marine & Offshore.

Marc Roussel, appointed Executive Vice-President Urbanization and Assurance, joined Bureau Veritas in 2015 and has held multiple leadership roles across the company. His most recent role was Executive Vice-president, Commodities, Industry & Facilities, France.

Catherine Chen remains Executive Vice-President Consumer Products Services. She joined Bureau Veritas in 2005 and has held various sales, marketing, and operational leadership roles in Consumer Product Services. Catherine will continue to connect Consumer Products & Technology Product Lines, as Executive Vice-President, Consumer Products Services.

Laurent Louail, appointed Executive Vice-President Chief Performance Officer, joined Bureau Veritas in 1995 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Commodities, Industry & Facilities in Southwest Europe, before becoming Executive Vice-President, Global Business Lines & Performance.

Juliano Cardoso remains Executive Vice-President Corporate Development & Sustainability. He joined Bureau Veritas in 1999 and has held leadership roles across the company. Juliano will continue to lead our corporate development and sustainability efforts in his current role as Executive Vice-President, Corporate Development & Sustainability.

Philipp Karmires remains Executive Vice-President Chief Digital & Innovation Officer. He is a senior executive with over 20 years of experience in digital transformation, enterprise software and product innovation. Philipp joined Bureau Veritas in 2024 and will continue to lead the DxT (Digital & Technology) function as Executive Vice-President, Chief Digital & Innovation Officer.

François Chabas remains Executive Vice-President Chief Financial Officer. He joined Bureau Veritas in 2003, holding finance roles with increasing responsibility before becoming Chief Financial Officer in 2014. François will continue to lead the finance function as Executive Vice-President, Finance.

Maria Lorente Fraguas remains Executive Vice-President Chief People Officer. She joined Bureau Veritas in 2024 after holding senior operational and human resources roles in international companies across multiple countries. Maria will continue to lead the people function as Executive Vice-President, Chief People Officer.

Béatrice Place-Faget remains Executive Vice-President Legal & Internal Audit. She joined Bureau Veritas in 2020 after serving as general counsel for other companies in France. Béatrice will continue to lead the legal and compliance function as Executive Vice-President, Legal affairs & Internal Audit.

Our information is certified with blockchain technology.

Check that this press release is genuine at www.wiztrust.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250618391984/en/

Permalink

https://www.aetoswire.com/en/news/1806202547470

Contacts

ANALYST/INVESTOR CONTACTS

Laurent Brunelle

+33 (0)1 55 24 76 09

laurent.brunelle@bureauveritas.com

Colin Verbrugghe

+33 (0)1 55 24 77 80

colin.verbrugghe@bureauveritas.com

MEDIA

Anette Rey

+33 (0)6 69 79 84 88

anette.rey@bureauveritas.com

Martin Bovo

+33 (0) 6 14 46 79 94

martin.bovo@bureauveritas.com

Karine Ansart

karine.ansart@bureauveritas.com

Inès Lagoutte

ines.lagoutte@bureauveritas.com

Fiber Global Raises $20 Million Series A to Scale Circular Building Materials Platform

 Funding Led by DBL Partners Will Accelerate Fiber Global’s U.S. Manufacturing Expansion to Turn Abundant Global Waste Streams into High-Performance Products

(BUSINESS WIRE) -- Fiber Global, a pioneer in sustainable building materials, today announced it has raised $20 million in Series A funding. The round was led by DBL Partners, with Founder and Managing Partner Ira Ehrenpreis joining the Board of Directors. The capital will support Fiber Global’s mission to transform abundant global waste streams into scalable, sustainable building materials, starting with expansion of its U.S. manufacturing footprint.

Fiber Global’s proprietary technology platform converts abundant global waste streams into durable, high-performing building materials capable of outperforming existing solutions with a dramatically lower carbon footprint. Manufactured in the United States, Fiber Global’s products are also formaldehyde free, have zero harmful volatile organic compounds (VOCs), and are UL GREENGUARD GOLD certified. With construction materials responsible for over 10% of global greenhouse gas emissions, Fiber Global aims to lead the transition toward a climate-positive, affordable, and resilient building materials industry through a circular manufacturing approach that also strengthens local economies.

“From day one, our relationship with DBL Partners and Ira Ehrenpreis has been invaluable,” said KC McCreery, Founder and CEO of Fiber Global. “Their team brings more than just investment; they actively engage and support our growth on a daily basis with intentionality. DBL Partners and Ira Ehrenpreis are truly part of the Fiber Global team, sharing our mission and vision of reclaiming tomorrow. This investment round provides us with the ability to continue rapidly scaling our United States manufacturing footprint and production capacity."

Over the past two and a half years, Fiber Global has focused intensely on the execution and scalability of reclaiming global waste streams to build more affordable, better performing, and truly sustainable products. The company is already partnering with leading materials companies to deploy its products across multiple building materials applications, offering a low-carbon alternative without compromising on performance or cost. DBL Partners has a long-standing track record of supporting transformative companies that rethink industry norms and apply deep innovation across both product and processes to redefine what is possible at scale.

“Fiber Global exemplifies the mission-driven, execution-oriented companies DBL seeks to back,” said Ira Ehrenpreis. “KC and his team are building a platform with the potential to revolutionize the building materials sector, combining sustainability, performance, and affordability at scale. Fiber Global is building a better and more economically compelling product that also has a superior environmental footprint, demonstrating how double bottom line is not about tradeoff or compromise but about winning with the best value proposition.”

With increasing global focus on the need to decarbonize the built environment and diversify the supply chains of key building materials, Fiber Global is positioned to meet a surge in demand from partners seeking high-performance, cost-effective, and environmentally cleaner alternatives. The Series A round validates the company’s commercial traction and technology and sets the stage for broader expansion in the years ahead.

About Fiber Global

Fiber Global is a climate technology company redefining building materials through circular innovation. With a mission to reclaim abundant global waste streams to create sustainable, high performing building materials, Fiber Global is driving the shift toward a more resourceful and resilient future. Founded in 2023, the company is headquartered in Brownsburg, IN. Learn more at www.fiberglobal.com.

About DBL Partners

DBL Partners is a pioneering impact investor and among the largest in the venture asset class. The firm invests in companies that can deliver both top-tier venture capital returns and enable social, environmental, and economic benefits. DBL Partners manages over $1.5B in assets, and has helped to scale industry-transforming companies across multiple sectors, including electric vehicles, the earth-space nexus, renewable energy, circular economy, and many others. More information can be found at: www.dbl.vc.

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding Fiber Global’s growth plans, market opportunities, product capabilities, and expected impacts. These statements are based on current assumptions and estimates and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements speak only as of the date of this release, and Fiber Global undertakes no obligation to update them in light of new information or future events.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250617520583/en/

Permalink
https://aetoswire.com/en/news/1706202547448

Contacts

publicrelations@fiberglobal.com

Daimler Truck, Mitsubishi Fuso, Hino et Toyota Motor Corporation concluent des accords définitifs sur l'intégration de Mitsubishi Fuso et Hino Motors

 

 

• Daimler Truck et Toyota Motor Corporation ont le plaisir d’annoncer la conclusion d’accords définitifs en vue de l’intégration de Mitsubishi Fuso et Hino sur un pied d’égalité.
• Le regroupement des forces permettra d'établir une nouvelle puissance japonaise dans le secteur des camions, au bénéfice de toutes les parties prenantes.
• La nouvelle société combinée compte plus de 40 000 employés et dispose de l'envergure, des ressources et du leadership technologique nécessaires pour façonner l'avenir du secteur des véhicules industriels dans la région Asie-Pacifique et au-delà.
• L'objectif est que la nouvelle société holding cotée en bourse commence ses activités en avril 2026.

 

Daimler Truck AG (Présidente et PDG : Karin Rådström, ci-après « Daimler Truck »), Mitsubishi Fuso Truck and Bus Corporation (Président et PDG : Karl Deppen, ci-après « Mitsubishi Fuso »), Hino Motors Ltd. (Président et PDG : Satoshi Ogiso, ci-après « Hino ») et Toyota Motor Corporation (Président et PDG : Koji Sato, ci-après « Toyota ») ont conclu aujourd'hui des accords définitifs pour l'intégration de Mitsubishi Fuso et de Hino.

 

Détails de la collaboration (points principaux) :

• Mitsubishi Fuso et Hino s'intégreront sur un pied d'égalité et coopéreront dans les domaines du développement, de l'approvisionnement et de la production de véhicules industriels.
• L'objectif est que la nouvelle société holding cotée en bourse commence ses activités en avril 2026.
• Daimler Truck et Toyota s'efforceront de détenir chacun 25 % de la société holding (cotée en bourse) de Mitsubishi Fuso et Hino intégrés.
• La société holding prévoit de détenir 100 % de Mitsubishi Fuso et Hino.
• L'intention est de coter la société holding sur le Prime Market de la Bourse de Tokyo.
• PDG de la société holding : Karl Deppen
• Siège social : Tokyo (Japon)

 

De plus amples détails sur l'étendue et la nature de la collaboration, y compris le nom de la nouvelle société holding, devraient être annoncés au cours des prochains mois. L'opération sera finalisée sous réserve de l'approbation des conseils d'administration, des actionnaires et des autorités compétentes.

 

Les véhicules utilitaires soutiennent la vie quotidienne en assurant le transport de personnes et de marchandises. Ils représentent une forme essentielle de mobilité, pouvant être considérée comme une véritable « infrastructure sociale ». Dans le cadre de cette collaboration, les quatre entreprises ont cherché une manière significative de façonner l’avenir des véhicules utilitaires. Animées par le même désir de «contribuer à une société prospère grâce à la mobilité», elles poursuivent leur collaboration et sont aujourd’hui heureuses d’annoncer la prochaine étape prometteuse de ce partenariat.

 

En intégrant Mitsubishi Fuso et Hino Motors, les entreprises visent à améliorer l'efficacité de leurs activités dans des domaines tels que le développement, l'approvisionnement et la production. Elles espèrent ainsi améliorer considérablement la compétitivité des constructeurs japonais de véhicules utilitaires et renforcer les bases de l'industrie automobile au Japon et en Asie.

 

La nouvelle société holding sera fière d'apporter sa contribution aux clients, aux différentes parties prenantes et à l'industrie automobile en aidant à résoudre les problèmes liés aux véhicules industriels, tels que la neutralité carbone et l'efficacité logistique, tout en s'efforçant de créer une société de mobilité durable et prospère et de renforcer l'activité des véhicules commerciaux à l'échelle mondiale grâce au développement des technologies CASE (connectées, autonomes, partagées, électriques), y compris l'hydrogène.

Déclarations de chaque entreprise

Karin Rådström, PDG de Daimler Truck a affirmé : « L'intégration de Mitsubishi Fuso et de Hino Motors, désormais décidée, est véritablement historique. Nous réunissons deux partenaires solides pour former une entreprise encore plus forte et façonner avec succès la décarbonisation des transports. Ensemble, Mitsubishi Fuso et Hino Motors disposent d'un grand potentiel pour tirer parti de l'échelle - et l'échelle est la clé de la transformation technologique de notre industrie. Karl Deppen est un dirigeant expérimenté et puissant qui comprend l'ensemble de la chaîne de valeur de notre activité, et je suis donc convaincu qu'il peut amener la nouvelle société à un niveau supérieur ».

 

Pour sa part, Koji Sato, PDG de Toyota a dit : « Nous pensons que l'avenir est à construire ensemble. L'accord final d'aujourd'hui n'est pas un but mais une ligne de départ. Nos quatre entreprises, dont l'objectif est de parvenir à une société de mobilité durable, continueront à créer ensemble l'avenir des véhicules utilitaires ».

 

« C'est un grand jour pour toutes les parties prenantes. Nous façonnons le secteur en regroupant nos forces. Avec une nouvelle entreprise forte, nous combinons nos deux marques de confiance, nos ressources, nos compétences et notre expertise pour mieux soutenir nos clients dans leurs besoins de transport à l'avenir. Je suis honoré et enthousiaste d'être le leader désigné de la nouvelle société et je suis reconnaissant de la confiance et de l'encouragement de Toyota et de Daimler Truck pour que cela se produise », a souligné Karl Deppen, PDG de Mitsubishi Fuso et futur PDG de la société nouvelle holding.

 

Satoshi Ogiso, PDG de Hino a conclu : « La coopération entre ces quatre entreprises est une véritable ‘occasion unique’. Outre la synergie opérationnelle, nous pouvons nous attendre à une synergie incommensurable résultant de la synthèse de nos différentes cultures et climats. Animés par une aspiration commune, nous sommes convaincus de pouvoir bâtir une équipe forte et résiliente, fondée sur l’empathie mutuelle et la contribution à la société. En tant que nouvelle entreprise de véhicules commerciaux ancrée au Japon, nous œuvrons ensemble à la création d’un avenir meilleur ».

 

Pour en savoir plus sur Daimler Truck, veuillez consulter :

newsroom.daimlertruck.com et daimlertruck.com.

 

Déclarations prospectives :

Le présent document contient des déclarations prospectives qui reflètent notre point de vue actuel concernant des événements futurs. Les termes tels que « ambition », « objectif », « anticiper », « supposer », « croire », « estimer », « s’attendre à », « avoir l’intention de », « pouvoir », « planifier », « projeter », « devoir» et d’autres expressions similaires servent à identifier ces déclarations. Ces déclarations sont soumises à de nombreux risques et incertitudes, notamment une évolution défavorable de la conjoncture économique mondiale, en particulier une baisse de la demande sur nos marchés principaux; une détérioration de nos possibilités de refinancement sur les marchés du crédit et financiers; des cas de force majeure tels que des catastrophes naturelles, des pandémies, des actes de terrorisme, des troubles politiques, des conflits armés, des accidents industriels et leurs effets sur nos activités de vente, d’approvisionnement, de production ou de services financiers; des variations des taux de change, des droits de douane ou des dispositions relatives au commerce extérieur; une évolution des préférences des consommateurs; un éventuel manque d’acceptation de nos produits ou services limitant notre capacité à fixer des prix et à exploiter efficacement nos capacités de production; une hausse des prix des carburants ou des matières premières; une interruption de la production en raison de pénuries de matériaux, de grèves ou d’insolvabilité de fournisseurs; une baisse des prix de revente des véhicules d’occasion; la mise en œuvre effective de mesures de réduction des coûts et d’optimisation de l’efficacité; les perspectives commerciales des entreprises dans lesquelles nous détenons une participation significative; la mise en œuvre réussie de coopérations stratégiques et de coentreprises; des changements de lois, de réglementations ou de politiques publiques, notamment en matière d’émissions de véhicules, de consommation de carburant et de sécurité ; la résolution d’enquêtes gouvernementales en cours ou sollicitées par les autorités, ainsi que l’issue de procédures judiciaires en cours ou potentielles; et d'autres risques et incertitudes, dont certains sont décrits dans la section « Rapport sur les risques et opportunités » de notre Rapport Annuel actuel. Si un ou plusieurs de ces risques ou incertitudes se concrétisent, ou si les hypothèses sous-jacentes à nos déclarations prospectives s’avèrent incorrectes, les résultats réels pourraient différer sensiblement de ceux exprimés ou sous-entendus dans ces déclarations. Nous ne prévoyons pas, et n’assumons aucune obligation de mettre à jour ces déclarations prospectives, celles-ci étant basées uniquement sur les circonstances en vigueur à la date de publication.

 

Daimler Truck en un coup d’œil

Daimler Truck Holding AG (« Daimler Truck ») est l’un des plus grands fabricants mondiaux de véhicules utilitaires, avec plus de 40 sites principaux et plus de 100 000 employés à travers le monde. Les fondateurs de Daimler Truck ont inventé l’industrie moderne du transport il y a environ 125 ans grâce à leurs camions et autobus. Inchangées à ce jour, les ambitions de l’entreprise se concentrent sur un seul objectif : Daimler Truck œuvre pour tous ceux qui maintiennent le monde en mouvement. Ses clients permettent aux personnes d’être mobiles et de transporter les marchandises de manière fiable, ponctuelle et sécurisée. Daimler Truck fournit les technologies, produits et services nécessaires pour y parvenir. Ceci inclut également la transition vers une conduite neutre en CO2. L’entreprise s’efforce de faire du transport durable un succès, en s’appuyant sur une connaissance technologique approfondie et une compréhension claire des besoins de ses clients. Les activités commerciales de Daimler Truck sont organisées en cinq segments de reporting : Trucks North America (TN), avec les marques de camions Freightliner et Western Star ainsi que la marque de bus scolaires Thomas Built Buses ; Trucks Asia (TA), avec les marques de véhicules utilitaires FUSO et RIZON ; Mercedes-Benz Trucks (MBT), avec la marque éponyme et BharatBenz ; Daimler Buses (DB), avec les marques de bus Mercedes-Benz et Setra ; Daimler Truck Financial Services (DTFS), qui constitue le cinquième segment. La gamme de produits des segments camions comprend des camions légers, moyens et lourds pour le transport longue distance, la distribution, les travaux de construction, ainsi que des véhicules spéciaux principalement utilisés dans les secteurs municipaux et professionnels. La gamme du segment bus comprend des bus urbains, des bus scolaires, des bus interurbains, des autocars et des châssis de bus. En plus de la vente de véhicules utilitaires neufs et d’occasion, l’entreprise propose également des services après-vente et des solutions de connectivité.

 

Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Permalink
https://aetoswire.com/fr/news/intp17062025c-1

Contacts

Jörg Howe, +49 160 8698000, joerg.howe@daimlertruck.com

Thomas Hövermann, + 49 176 30984119, thomas.hoevermann@daimlertruck.com

Daimler Truck, Mitsubishi Fuso, Hino and Toyota Motor Corporation conclude Definitive Agreements on integrating Mitsubishi Fuso and Hino Motors

 

• Daimler Truck and Toyota Motor Corporation pleased to announce conclusion of Definitive Agreements to integrate Mitsubishi Fuso and Hino on equal footing
• Bundling forces to establish a new strong Japanese truck powerhouse to the benefit of all stakeholders
• New combined company with over 40,000 employees with the scale, resources, and technology leadership to shape the future of the commercial vehicle landscape in the Asia-Pacific region and beyond
• Aiming for new listed holding company to start operations in April 2026

 

Daimler Truck AG (President and CEO: Karin Rådström, hereafter “Daimler Truck”) Mitsubishi Fuso Truck and Bus Corporation (President and CEO: Karl Deppen, hereafter “Mitsubishi Fuso”), Hino Motors Ltd. (President and CEO: Satoshi Ogiso, hereafter “Hino”) and Toyota Motor Corporation (President and CEO: Koji Sato, hereafter “Toyota”) today concluded Definitive Agreements for the integration of Mitsubishi Fuso and Hino.

Collaboration Details (main points):

• Mitsubishi Fuso and Hino will integrate on an equal footing and cooperate in the areas of commercial vehicle development, procurement, and production.

• Aiming for new listed holding company to start operations in April 2026.
• Daimler Truck and Toyota will each aim to own 25% of the (listed) holding company of the integrated Mitsubishi Fuso and Hino.
• The holding company plans to own 100% of Mitsubishi Fuso and Hino.
• The intention is to list the holding company on the Prime Market of the Tokyo Stock Exchange.
• Holding company CEO: Karl Deppen
• Headquarter location: Tokyo (Japan)

 

Further details on the scope and nature of the collaboration, including the name of the new holding company, are intended to be announced over the coming months. The deal will proceed to closing subject to approval from the relevant boards, shareholders and authorities.

Commercial vehicles support daily life through the movement of people and goods and are an important form of mobility that can be considered "social infrastructure”. With this collaboration, the four companies have been seeking a meaningful way to create the future of commercial vehicles. Based on the common desire to “contribute to an affluent society through mobility”, the four companies are proceeding with their collaboration and are now pleased to announce the exciting next stage.

By integrating Mitsubishi Fuso and Hino Motors, the companies aim to improve business efficiency in areas such as development, procurement and production. With this, they expect to significantly enhance the competitiveness of Japanese commercial vehicle manufacturers and strengthen the foundation of the automotive industry in Japan and Asia.

The new holding company shall proudly contribute to customers, various stakeholders, and the automotive industry by helping to solve issues surrounding commercial vehicles, such as carbon neutrality and logistics efficiency, while striving to realize a sustainable and prosperous mobility society and to strengthen the commercial vehicle business globally through the development of CASE technologies (Connected, Autonomous, Shared, Electric), including hydrogen.

Statements from each company

Karin Rådström, CEO, Daimler Truck: “The now decided integration of Mitsubishi Fuso and Hino Motors is truly historic. We are bringing together two strong partners to form an even stronger company and to successfully shape the decarbonization of transportation. Together, Mitsubishi Fuso and Hino Motors have great potential to leverage scale – and scale is key to win in the technological transformation of our industry. Karl Deppen is an experienced and strong leader who comprehends the whole value chain of our business, and I’m therefore convinced that he can bring the new company to the next level.”

Koji Sato, CEO, Toyota: “We believe that the future is for us to build together. Today’s final agreement is not the goal but the starting line. Our four companies, aiming to achieve a sustainable mobility society, will continue to create the future of commercial vehicles together.”

Karl Deppen, CEO, Mitsubishi Fuso and designated CEO of new holding company: “Today is a great day for all our stakeholders. We are shaping the industry by bundling our strengths. With a strong new company we combine our two trusted brands, our resources, competencies and expertise to even better support our customers in their transportation needs in the future. I feel honored and excited to be the designated leader of the new company and am grateful for the trust and encouragement from Toyota and Daimler Truck to make it happen.”

Satoshi Ogiso, CEO, Hino: “Cooperation among these 4 companies is truly “once-in-a-lifetime opportunity”. In addition to operational synergy, we can expect immeasurable synergy affection from synthesizing different culture and climate of us. Under commonly aimed aspiration, we are confident with building strong and resilient team to empathizing with each other and contributing to society. As a new commercial vehicle company rooted in Japan, we collaboratively create ever better future.”

Further information on Daimler Truck is available at:

newsroom.daimlertruck.com and daimlertruck.com

Forward-looking statements:

This document contains forward-looking statements that reflect our current views about future events. The words “aim”, “ambition”, “anticipate”, “assume”, “believe”, “estimate”, “expect”, “intend”, “may”,” can”, “could”, “plan”, “project”, “should” and similar expressions are used to identify forward-looking statements. These statements are subject to many risks and uncertainties, including an adverse development of global economic conditions, in particular a decline of demand in our most important markets; a deterioration of our refinancing possibilities on the credit and financial markets; events of force majeure including natural disasters, pandemics, acts of terrorism, political unrest, armed conflicts, industrial accidents and their effects on our sales, purchasing, production or financial services activities; changes in currency exchange rates, customs and foreign trade provisions; a shift in consumer preferences; a possible lack of acceptance of our products or services which limits our ability to achieve prices and adequately utilize our production capacities; price increases for fuel or raw materials; disruption of production due to shortages of materials, labor strikes or supplier insolvencies; a decline in resale prices of used vehicles; the effective implementation of cost-reduction and efficiency-optimization measures; the business outlook for companies in which we hold a significant equity interest; the successful implementation of strategic cooperations and joint ventures; changes in laws, regulations and government policies, particularly those relating to vehicle emissions, fuel economy and safety; the resolution of pending government investigations or of investigations requested by governments and the conclusion of pending or threatened future legal proceedings; and other risks and uncertainties, some of which are described under the heading “Risk and Opportunity Report” in the current Annual Report. If any of these risks and uncertainties materializes, or if the assumptions underlying any of our forward-looking statements prove to be incorrect, the actual results may be materially different from those we express or imply by such statements. We do not intend or assume any obligation to update these forward-looking statements since they are based solely on the circumstances at the date of publication.

Daimler Truck at a glance

Daimler Truck Holding AG ("Daimler Truck") is one of the world's largest commercial vehicle manufacturers, with over 40 main locations and more than 100,000 employees around the globe. The founders of Daimler Truck have invented the modern transportation industry with their trucks and buses a good 125 years ago. Unchanged to this day, the company's aspirations are dedicated to one purpose: Daimler Truck works for all who keep the world moving. Its customers enable people to be mobile and get goods to their destinations reliably, on time, and safely. Daimler Truck provides the technologies, products, and services for them to do so. This also applies to the transformation to CO2-neutral driving. The company is striving to make sustainable transport a success, with profound technological knowledge and a clear view of its customers' needs. Daimler Truck's business activities are structured in five reporting segments: Trucks North America (TN) with the truck brands Freightliner and Western Star and the school bus brand Thomas Built Buses. Trucks Asia (TA) with the FUSO and RIZON commercial vehicle brands. Mercedes-Benz Trucks (MBT) with the truck brand of the same name and BharatBenz. Daimler Buses (DB) with the Mercedes-Benz and Setra bus brands. Daimler Truck's new Financial Services business (DTFS) constitutes the fifth segment. The product range in the truck segments includes light, medium and heavy trucks for long-distance, distribution and construction traffic and special-purpose vehicles used mainly in the municipal and vocational sector. The product range of the bus segment includes city buses, school buses and intercity buses, coaches and bus chassis. In addition to the sale of new and used commercial vehicles, the company also offers aftersales services and connectivity solutions.

Permalink
https://aetoswire.com/en/news/dtmea1762025

Contacts

Jörg Howe, +49 160 8698000, joerg.howe@daimlertruck.com

Thomas Hövermann, + 49 176 30984119, thomas.hoevermann@daimlertruck.com